LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health solutions for Latin America, announced on July 31, 2026, that its Venezuelan subsidiary, LATAMEDAI VE, has signed an agreement with the Venezuelan Institute for Scientific Research (IVIC) to develop a digital platform module. This module is intended to provide authorized business and institutional users with streamlined access to IVIC's laboratory and scientific services.
The proposed platform is designed to centralize digital workflows for organizations seeking services in healthcare, pharmaceuticals, food production, agriculture, and related industries. Users would be able to request services, schedule appointments, monitor request status, access approved reports, and complete payment processes through a single interface. The specific services available would be determined by IVIC, ensuring alignment with technical, operational, and legal requirements.
Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized the importance of this collaboration: "This agreement represents an opportunity to apply our technology to an important area of scientific and enterprise service delivery. Our objective is to work with IVIC to develop a responsible digital framework that makes it easier for authorized users to request services, manage appointments, monitor processes, and access approved information through a centralized platform."
This initiative marks a strategic expansion for LataMed AI, which has primarily focused on patient-facing telemedicine. By venturing into institutional and enterprise workflows, the company aims to demonstrate the versatility of its technology in supporting scientific services and digital documentation. Management believes that if successfully implemented, this module could serve as a template for similar institutional environments across Latin America, subject to separate agreements and regulatory approvals.
The agreement outlines a collaborative process for defining functional requirements, user-access procedures, data architecture, payment workflows, and document-management capabilities. Both parties will also establish protocols for handling sensitive laboratory information, ensuring compliance with security and privacy standards. However, the final functionality and implementation timeline remain subject to continued development and testing.
This partnership aligns with LataMed AI's broader strategy of building digital infrastructure that connects various stakeholders in the healthcare ecosystem, including patients, providers, pharmacies, insurers, and institutions. By extending its capabilities to laboratory services, the company is positioning itself as a comprehensive digital health partner in the region.
While the agreement sets the stage for development, it does not guarantee specific outcomes such as implementation dates, user adoption, or revenue generation. The company has cautioned that forward-looking statements involve risks, including technical challenges, regulatory hurdles, and the need for additional financing. Nonetheless, this collaboration with IVIC represents a significant step toward diversifying LataMed AI's offerings and establishing a foothold in the scientific services sector.
For more information about LataMed AI and its initiatives, interested parties can visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
